sutrobio.com (STRO) - חוב להון עצמי

Sutro Biopharma, Inc. (STRO) utilizes artificial intelligence to design immunotherapies by automating synthesis within bioreactors. Serving as an assessment tool, the total debt-to-equity chart recorded a value of 0.00. The business relies on cell-free protein synthesis, which accelerates development and enables the collection of licensing fees from industry behemoths. The company's stability is based on external support and the successful validation of its platform's efficacy, while its cash reserve remains sufficient.

Sutro Biopharma, Inc. (STRO) automates the creation of oncology antibodies via XpressCF robotic platforms, which requires significant capital expenditures in technology. By analyzing the leverage ratio—total debt to equity—an investor assesses the proportion of borrowed funds within the balance sheet structure relative to equity, determining the company's resilience to interest rate shocks and the risk of default amid monetary policy tightening.